Annual cost-savings with the implementation of estrogen-receptor-only testing on Ductal Carcinoma in Situ specimens.

Jaclyn A Gellings,Chandler S Cortina,Julie M Jorns,Morgan K Johnson,Chiang-Ching Huang,Amanda L Kong

American journal of surgery（2023）

引用 0|浏览3

暂无评分

摘要

PR testing for DCIS should be reserved only for patients with ER- DCIS undergoing breast conservation to determine the utility of adjuvant endocrine therapy.

查看译文

关键词

Cost savings,Ductal carcinoma in situ,Omission of progesterone testing

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要